Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: A randomized controlled trial

JAMA

Volumn 300, Issue 18, 2008, Pages 2134-2141

  Ogawa, Hisao ^a   Nakayama, Masafumi ^a   Morimoto, Takeshi ^b   Uemura, Shiro ^c   Kanauchi, Masao ^c   Doi, Naofumi ^c   Jinnouchi, Hideaki ^d   Sugiyama, Seigo ^a   Saito, Yoshihiko ^c  

^a KUMAMOTO UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c NARA MEDICAL UNIVERSITY   (Japan)

^d Jinnouchi Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA GLUCOSIDASE INHIBITOR; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIGUANIDE DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; SULFONYLUREA; THIAZOLIDINE DERIVATIVE; ANTITHROMBOCYTIC AGENT;

ADULT; AGED; ANEMIA; ARTERY DISEASE; ARTICLE; ASTHMA; ATHEROSCLEROSIS; BLEEDING; BLEEDING DISORDER; CLINICAL TRIAL; COLON DIVERTICULOSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG WITHDRAWAL; DUODENUM ULCER; DYSLIPIDEMIA; EPISTAXIS; FEMALE; FOLLOW UP; GASTRIC ULCER BLEEDING; GASTRITIS; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HEMATURIA; HEMORRHOID; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETINA HEMORRHAGE; STOMACH ULCER; STROKE; SUBCUTANEOUS HEMORRHAGE; SUBDURAL HEMATOMA; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; CARDIOVASCULAR DISEASE; DIABETIC ANGIOPATHY; DOUBLE BLIND PROCEDURE; MIDDLE AGED; MULTICENTER STUDY;

ADULT; AGED; AGED, 80 AND OVER; ASPIRIN; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS;

EID: 56149113603     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2008.623     Document Type: Article

References (37)

1. Wolf PA, D'Agostino RB, Belanger AJ, Kannel WB. Probability of stroke: a risk profile from the Framingham study. Stroke. 1991;22(3):312-318.
2. Murabito JM, D'Agostino RB, Silbershatz H, Wilson WF. Intermittent claudication: a risk profile from the Framingham Heart Study. Circulation. 1997;96(1):44-49.
3. Kannel WB, D'Agostino RB, Silbershatz H, Belanger AJ, Wilson PW, Levy D. Profile for estimating risk of heart failure. Arch Intern Med. 1999;159(11):1197-1204.
4. Kannel WB, McGee DL. Diabetes and cardiovascular disease: the Framingham study. JAMA. 1979;241(19):2035-2038.
5. Kannel WB, McGee DL. Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham study. Diabetes Care. 1979;2(2):120-126.
6. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339(4):229-234.
7. The RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet. 1990;336(8719):827-830.
8. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. J Am Coll Cardiol. 1988;12(6)(suppl A):3A-13A.
9. Yasue H, Ogawa H, Tanaka H, et al; Japanese Antiplatelets Myocardial Infarction Study ( JAMIS) Investigators. Effects of aspirin and trapidilon cardiovascular events after acute myocardial infarction. Am J Cardiol. 1999;83(9):1308-1313.
10. Rydén L, Standl E, Bartnik M,et al; Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Guidelines on diabetes, prediabetes, and cardiovascular diseases: executive summary. Eur Heart J. 2007;28(1):88-136.
11. American Diabetes Association. Standards of medical care in diabetes: 2007. Diabetes Care. 2007;30(suppl 1):S4-S41.
12. Canadian Diabetes Association 2003 clinical practice guidelines for the prevention and management of diabetes in Canada. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. http://mdm.ca/cpgsnew/cpgs/ search/english/help/2CDA2.htm. Accessed October 14, 2008.
13. Diabetes Australia Guideline Development Consortium, National Medical Research Council. National Evidence Based Guidelines for the Management of Type 2 Diabetes Mellitus: Part 5, Prevention and Detection of Macrovascular Disease in Type 2 Diabetes. Sydney, Australia: Australian Centre for Diabetes Strategies; 2004.
14. Evidence-Based Best Practice Guideline: Management of Type 2 Diabetes. Wellington, New Zealand: New Zealand Guidelines Group; 2003.
15. Hutchinson A, McIntosh A, Griffiths CJ, et al. Clinical Guidelines and Evidence Review for Type 2 Diabetes. Blood Pressure Management. Sheffield, England: School of Health and Related Research (ScHARR), University of Sheffield; 2002.
16. Colwell JA; American Diabetes Association. Aspirin therapy in diabetes. Diabetes Care. 2003;26(suppl 1):S87-S88.
17. Sirois C, Poirier P, Moisan J, Grégoire JP. The benefit of aspirin therapy in type 2 diabetes: what is the evidence? Int J Cardiol. 2008;129(2):172-179.
18. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med. 1989;321(3):129-135.
19. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324(7329):71-86.
20. Sacco M, Pellegrini F, Roncaglioni MC, Avanzini F, Tognoni G, Nicolucci A; PPP Collaborative Group. Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial. Diabetes Care. 2003;26(12):3264-3272.
21. de Gaetano G; Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomized trial in general practice. Lancet. 2001;357(9250):89-95.
22. Fujishima M, Kiyohara Y, Kato I, et al. Diabetes and cardiovascular disease in a prospective population survey in Japan: the Hisayama Study. Diabetes. 1996;45(suppl 3):S14-S16.
23. Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose: the Funagata Diabetes Study. Diabetes Care. 1999;22(6):920-924.
24. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial: HOT Study Group. Lancet. 1998;351(9118):1755-1762.
25. Fox CS, Coady S, Sorlie PD, et al. Increasing cardiovascular disease burden due to diabetes mellitus: the Framingham Heart Study. Circulation. 2007;115(12):1544-1550.
26. International Diabetes Federation. Diabetes Atlas. 2nd ed; 2003. http://www.eatlas.idf.org/webdata/docs/Atlas%202003-Summary.pdf. Accessed September 22, 2008.
27. Sone H, Ito H, Ohashi Y, Akanuma Y, Yamada N; Japan Diabetes Complication Study Group. Obesity and type 2 diabetes in Japanese patients. Lancet. 2003;361(9351):85.
28. Deurenberg P, Yap M, van Staveren WA. Body mass index and percent body fat: a meta analysis among different ethnic groups. Int J Obes Relat Metab Disord. 1998;22(12):1164-1171.
29. Bartolucci AA, Howard G. Meta-analysis of data from six preliminary prevention trials of cardiovascular events using aspirin. Am J Cardiol. 2006;98(6):746-750.
30. Morimoto T, Fukui T, Lee TH, Matsui K. Application of US guidelines in other countries: aspirin for the primary prevention of cardiovascular events in Japan. Am J Med. 2004;117(7):459-468.
31. Hayden M, Pignone M, Phillips C, Mulrow C. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the US Preventive Services Task Force. Ann Intern Med. 2002;136(2):161-172.
32. Morimoto T, Nakayama M, Saito Y, Ogawa H. Aspirin for primary prevention of atherosclerotic disease in Japan. J Atheroscler Thromb. 2007;14(4):159-166.
33. Yamada Y, Metoki N, Yoshida H, et al. Genetic factors for ischemic and hemorrhagic stroke in Japanese individuals. Stroke. 2008;39(8):2211-2218.
34. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837-853.
35. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352(9131):854-865.
36. ADVANCE Collaborative Group; Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560-2572.
37. Action to Control Cardiovascular Risk in Diabetes Study Group; Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545-2559.